Search | Clinical Trials Finder

Conditions: Concussion, Mild, Traumatic Brain Injury, Mild
Interventions: Magnesium, Placebo; Dietary Supplement · Drug
Lead sponsor: Corewell Health South; Other
Eligibility: 12 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Saint Joseph, Michigan

Conditions: Arrhythmias, Cardiac, Atrial Fibrillation
Interventions: Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation; Drug
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Schizophrenia
Interventions: placebo, Ziprasidone oral capsules; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 46
States / cities: Birmingham, Alabama • San Diego, California • Stanford, California + 34 more

Conditions: HIV
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 20 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gingivitis
Interventions: Stannous fluoride; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions: NG101, Placebo; Drug
Lead sponsor: Neurogastrx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 83
States / cities: Dothan, Alabama • Foley, Alabama • Mobile, Alabama + 69 more

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 25 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk, Gestational Diabetes, Gestational Diabetes Mellitus in the Puerperium
Interventions: Immediate inpatient postpartum OGTT, Standard of care 4-12 week postpartum OGTT; Diagnostic Test
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
Interventions: iseganan HCl oral solution, management of therapy complications; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Phelan-McDermid Syndrome
Interventions: NNZ-2591; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Houston, Texas

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more

Conditions: Arteriosclerosis, Hypercholesterolaemia
Interventions: Enlicitide Decanoate, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14,550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 132
States / cities: Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 113 more

Conditions: Allergic Reaction
Interventions: DESF, Epinephrine Injection; Drug
Lead sponsor: Aquestive Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Crohn's Disease
Interventions: GSK1605786A, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 54
States / cities: Little Rock, Arizona • Tucson, Arizona • La Jolla, California + 48 more

Conditions: Healthy Participants
Interventions: PF-07293893, Placebo, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Aggressive Periodontitis
Interventions: Diseased periodontal treatment, Conventional periodontal treatment; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 90 Years
Enrollment: 514 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2022
U.S. locations: 10
States / cities: Brooker, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 6 more

Conditions: Psoriasis
Interventions: CEP-701 20mg, CEP-701 40mg, CEP-701 60mg, CEP-701 80mg; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: Winston-Salem, North Carolina • Dallas, Texas • Norfolk, Virginia

Conditions: Muscular Atrophy, Spinal
Interventions: Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: DC-806, Itraconazole, Carbamazepine; Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Oral Health
Interventions: Stannous Fluoride Toothpaste (Sensodyne Repair and Protect), Regular Fluoride Toothpaste (Colgate Cavity Protection); Other
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Oral Cancer
Interventions: Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach, Classification of Oral Microbiome Using taxonomic approach; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 92 Years
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1992 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Arterial Hypertension
Interventions: GB002 (seralutinib), Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: Gossamer Bio USA, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 15
States / cities: Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more

Conditions: HIV, HIV Pre-exposure Prophylaxis
Interventions: MK-8527, Placebo to MK-8527; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: North Hollywood, California • San Francisco, California • Hallandale, Florida + 7 more

Conditions: Oral Cavity Cancer, Head and Neck Cancers - Tonsils, Esophageal Cancer, Laryngeal Cancer, Oropharynx Cancer, Mediastinal Cancer, Chest Wall Tumor, Radiation Mucositis
Interventions: 100% Aloe Vera Juice, Magic Mouthwash, Salt and Baking soda rinse, Carafate; Dietary Supplement · Combination Product · Drug
Lead sponsor: Covenant Health Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Knoxville, Tennessee

Search by objective public record fields.

Mag Con: Efficacy of Oral Mag. in Acute Concussion in Adolescents

Feasibility and Safety of IV Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir

Stannous Fluoride and Gingivitis

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis

Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids

A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE

Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants

Mechanisms and Treatment Response of Aggressive Periodontitis in Children

Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants

A Study to Evaluate the Effect of a Stannous Fluoride Toothpaste on the Oral Microbiome

The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis